

Clinical Workshop at CPSA 2014 – Building a Better Clinical Mass Spectrometry Lab

Opening remarks, perspectives on what we currently do in clinical MS quantitation

*Timothy Garrett, University of Florida*

MS to screen multiple metabolites – how you design and validate for population screening in the hands of non-clinical chemists and non-mass spectrometrists

*Donald Chace, Pediatrix Analytical*

Case Studies in Start Ups and Scale Ups of LC/MS Drug Testing Labs: Challenges and Solutions in Achieving Sufficient Capability and Effective Workflows

*Mark Hayward, Active Ingredient Technologies*

Some Thoughts on Biomarker Translation

*Randall Nelson, Arizona State University*

Break - Lunch

Enabling Sensitivity and Ease-of-use through Nanospray Integration

*Gary Valaskovic, New Objective*

Challenges of Quantitative Dried Blood Spot Analysis from the Clinic

*Kenneth Lewis, OpAns*

Strategies for Developing and Implementing Initial LC-MS-Based Biomarker Assays in Drug Discovery

*Tim Olah, Bristol-Myers Squibb*